The Wistar Institute

Thomas Jefferson University

Other

Biotechnology Foundation, Inc.

Hilary Koprowski

Zenon Steplewski

Douglas Craig Hooper

Meenhard Herlyn

Bernhard Dietzschold

Anna Modelska

Carlo M Croce

Vidadi Yusibov

Dorothee Herlyn

Vyacheslav Andrianov

Alban J Linnenbach

Zhen Fang Fu

Alagarsamy Srinivisan

Peter S Carlson

Charles E Rupprecht

Eric Wickstrom

David Kritchevsky

Walter U Gerhard

Natalia Pogrebnyak

Elaine C DeFreitas

Frank H Michaels

Ewa Rakowicz-Szulczynska

Mykola Borysyuk

Tadeusz J Wiktor

Jan Thurin

Kenneth F Mitchell

Alonzo Ross

Kevin J Reagan

Magdelena Thurin

Mykola Borsyuk

Maxim Golovkin

Magdalena Thurin

Stanislaw Szala

Laura Jane Conway

John L Farber

Hanna Makolska

Elaine Defreitas

The present invention relates to a genetically modified plant having an increased amount of oil in its green biomass as compared to the oil in the green biomass of its non-genetically modified counterpart. The plants may be used for producing bio-fuels such as biodiesel fuel.

Engineered biomass with increased oil production

Engineered tobacco biomass with increased oil production

Methods of in vitro propagation of plants of the genusare described, including, in particular embodiments, plants of the speciesand. Methods of producing transgenic plants of the genusare also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Uses for Yerba Santa

The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.

Soluble variants of type I membrane proteins, and methods of using them

A fusion capsid protein comprising a plant virus capsid protein fused to an antigenic polypeptide is used as a molecule for presentation of that polypeptide to the immune system of an animal such as a human. The plant virus capsid protein is that of an alfalfa mosaic virus (AlMV) or ilarvirus.

Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid

Chimeric viral proteins and nucleic acid constructs that code for them and are useful as therapeutic agents are disclosed.

Chimeric viral proteins

Oligodeoxynucleotides complementary to genomic RNA of a negative-stranded nonsegmented RNA virus are provided. Methods of inhibiting infection of cells by a negative-stranded nonsegmented RNA virus and treating animals infected with a negative-stranded nonsegmented RNA virus using these oligodeoxynucleotides are also provided.

Antigenomic oligodeoxynucleotides for treatment of infection by negative-stranded nonsegmented RNA viruses

Chimeric viral proteins and nucleic acid constructs that code for them and are useful as therapeutic agents.

Methods of enhancing an antigen-induced immune response through use of a ribonucleocapsid complex are provided. Composition containing a ribonucleocapsid complex and an antigen which are capable of enhancing the immune response to the antigen are also provided.

Viral ribonucleocapsid as an immunological enhancer

Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins

A process for the synthesis and delivery of bioactive compounds, compounds that have a therapeutic, biochemical, or immunologic, effect on an animal, such as human. In the process, clavibacter is genetically altered so that it synthesizes the bioactive compound. A plant may be infected with the genetically altered clavibacter and used an as oral delivery system.

Synthesis of immunologic, therapeutic and prophylactic compounds by

The process of treating a disease of the central nervous system with an agent from one or more of the following three classes of agents: (1) nitric oxide scavengers, (2) peroxynitrite scavengers, and (3) agents that either interfere with the synthesis of iNOS in the cell or the enzymatic activity of iNOS in the cell.

Treatment of diseases of the central nervous system using uric acid as a

Pharmaceutical compositions that comprise a pharmaceutically acceptable carrier or diluent and a antibodies that each comprise at least a portion of the variable region from MAb 1112-1 are disclosed. Methods of treating individuals suspected of exposure to rabies are disclosed.

Methods for treating post-exposure rabies and anti-rabies compositions

The human tumor-associated antigen CO-029 is a monoclonal antibody-defined, 27-34 kDa cell surface glycoprotein. A full-length cDNA clone for CO-029 is described. When transiently expressed in COS cells, the cDNA clone directs the synthesis of an antigen reactive with monoclonal antibody CO-029 in mixed hemadsorption and immunoblot assays. Sequence analysis reveals that CO-029 belongs to a family of cell surface antigens which includes the melanoma-associated antigen ME491, the leukocyte cell surface antigen CD37, and the Sm23 antigen of the parasitic helminth Schistosoma mansoni.

DNA and polypeptide for tumor-associated antigen CO-029

The present invention provides a method for selecting from among many monoclonal antibodies capable of binding to a surface antigen on a tumor cell, the antibody which also can internalize into the cell and exert an appropriate molecular effect on the level of gene regulation in the tumor cell. Such antibodies can most effectively be employed to damage the tumor cell.

Methods for screening monoclonal antibodies for therapeutic use

Growing community of inventors

Wynnewood, PA, United States of America

Hilary Koprowski